Document is current
Any future updates will be listed below
-
Authors
Barmpa, Kyriaki
Saraiva, Claudia
Lopez-Pigozzi, Diego https://orcid.org/0000-0002-6178-5951
Gomez-Giro, Gemma
Gabassi, Elisa https://orcid.org/0000-0001-6053-503X
Spitz, Sarah
Brandauer, Konstanze
Rodriguez Gatica, Juan E. https://orcid.org/0000-0003-4123-0104
Antony, Paul https://orcid.org/0000-0002-0450-9301
Robertson, Graham
Sabahi-Kaviani, Rahman
Bellapianta, Alessandro
Papastefanaki, Florentia
Luttge, Regina
Kubitscheck, Ulrich https://orcid.org/0000-0003-3750-5355
Salti, Ahmad https://orcid.org/0000-0002-7678-0125
Ertl, Peter
Bortolozzi, Mario
Matsas, Rebecca https://orcid.org/0000-0002-4027-348X
Edenhofer, Frank https://orcid.org/0000-0002-6489-714X
Schwamborn, Jens C. https://orcid.org/0000-0003-4496-0559
-
Funding
Funding for this research was provided by:
Fonds National de la Recherche Luxembourg (NTER/FWF/19/14117540/PDage, C22/BM/17193204/MidStriPD)
EC | Horizon 2020 Framework Programme (824070)
Deutsche Forschungsgemeinschaft (459047646, KU 2474/13-2)
- License Information
-
More Information
Article History
Received: 20 June 2024
Accepted: 14 November 2024
First Online: 23 November 2024
Competing interests
: J.C.S. is a co-inventor on a patent covering the generation of the here-described midbrain organoids (WO2017060884A1). Furthermore, J.C.S. is a co-founder and shareholder of the company OrganoTherapeutics which makes use of midbrain organoid technology. The other authors declare no competing interests.
: Ethics Review Panel (ERP) of the University of Luxembourg and the national Luxembourgish research ethics committee (CNER, Comité National d’Ethique de Recherche) have approved the work with induced pluripotent stem cells (iPSCs). CNER No. 201901/01; ivPD.
